Axalta Q2 sales rise 3% to $1.35 billion, but GAAP net income falls to $89 million
Axalta reported second-quarter 2026 net sales of $1.35 billion, up 3% year over year, and a record Adjusted EBITDA of $305 million. GAAP net income fell to $89 million from $110 million and diluted EPS to $0.41 from $0.50, mainly due to $31 million in higher merger and acquisition costs. The company's full-year 2026 outlook calls for Adjusted Diluted EPS of $2.55 to $2.70, and shareholders are asked to attend a Special General Meeting on August 5 on the merger of equals with AkzoNobel.
Key points
- Net sales of $1.35 billion, up 3% year over year; Adjusted EBITDA of $305 million, a quarterly record, up 5%
- Diluted EPS of $0.41 versus $0.50 a year earlier; net income of $89 million versus $110 million, reflecting an incremental $31 million in merger and acquisition costs
- Adjusted Diluted EPS of $0.72, a record quarter and up 13% year over year
- Full-year 2026 outlook: Adjusted EBITDA $1,140 million to $1,170 million; Adjusted Diluted EPS $2.55 to $2.70; Special General Meeting on August 5
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.